MaltSci 麦伴科研

Appearance

Popular Reports / rare-diseases

This report is written by MaltSci based on the latest literature and research findings

How does gene therapy treat rare genetic diseases? ​

Abstract ​

Gene therapy has emerged as a groundbreaking approach to treating rare genetic diseases, which collectively affect millions globally despite their individual rarity. Traditional treatments often focus on symptom management rather than addressing the underlying genetic causes, leading to a pressing need for effective therapies. Recent advancements in molecular biology and genetic engineering have facilitated innovative strategies that aim to correct or replace faulty genes, offering potential cures for these disorders. This report provides a comprehensive overview of gene therapy, including its definition, historical context, mechanisms of action, and applications in rare genetic diseases, highlighted by successful case studies and ongoing clinical trials. The report also discusses the challenges and limitations faced by the field, such as safety concerns, ethical considerations, and regulatory hurdles, which pose significant barriers to widespread adoption. Additionally, it explores future directions, including innovations in delivery methods and the potential for personalized medicine, emphasizing the importance of ongoing research to enhance the efficacy and accessibility of gene therapies. By synthesizing current research and clinical trials, this report aims to enhance understanding of gene therapy's potential and limitations, contributing to informed discussions on its role in modern medicine.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Overview of Gene Therapy
    • 2.1 Definition and Historical Context
    • 2.2 Mechanisms of Gene Therapy
  • 3 Applications in Rare Genetic Diseases
    • 3.1 Successful Case Studies
    • 3.2 Ongoing Clinical Trials
  • 4 Challenges and Limitations
    • 4.1 Safety Concerns
    • 4.2 Ethical Considerations
    • 4.3 Regulatory Hurdles
  • 5 Future Directions
    • 5.1 Innovations in Delivery Methods
    • 5.2 Potential for Personalized Medicine
  • 6 Conclusion

1 Introduction ​

Gene therapy has emerged as a groundbreaking approach to treating rare genetic diseases, which are often caused by mutations in specific genes. These diseases, while individually uncommon, collectively affect millions of people globally, leading to significant morbidity and mortality. Traditional treatment modalities have largely focused on managing symptoms rather than addressing the underlying genetic causes, resulting in limited therapeutic options for patients. Recent advancements in molecular biology and genetic engineering have paved the way for innovative therapeutic strategies that aim to correct or replace faulty genes, thereby providing a potential cure for these disorders [1][2].

The significance of gene therapy in the context of rare genetic diseases cannot be overstated. With over 4,000 protein-coding genes implicated in more than 6,000 genetic diseases, the need for effective treatments has never been more pressing [2]. Gene therapy offers a novel approach by directly targeting the genetic mutations responsible for these conditions, thereby not only alleviating symptoms but potentially curing the diseases altogether. This paradigm shift in treatment strategies highlights the promise of gene therapy as a transformative solution for patients suffering from rare genetic disorders [3].

Despite the optimism surrounding gene therapy, the field is still in its infancy, and several challenges remain. Safety concerns, ethical considerations, and regulatory hurdles pose significant barriers to the widespread adoption of gene therapies. For instance, issues related to vector delivery systems, immunogenicity, and long-term efficacy must be thoroughly addressed to ensure patient safety and therapeutic success [3][4]. Furthermore, the high costs associated with the development and manufacturing of gene therapies, particularly for ultra-rare diseases, complicate their accessibility [5].

This report aims to provide a comprehensive overview of gene therapy's role in treating rare genetic diseases. It will begin with an overview of gene therapy, including its definition, historical context, and mechanisms of action. Following this, we will explore the various applications of gene therapy in rare genetic disorders, highlighting successful case studies and ongoing clinical trials. The challenges and limitations of gene therapy will be discussed in detail, focusing on safety concerns, ethical considerations, and regulatory hurdles. Finally, we will examine future directions in the field, including innovations in delivery methods and the potential for personalized medicine.

By synthesizing current research and clinical trials, this report seeks to enhance understanding of gene therapy's potential and limitations, fostering informed discussions on its role in modern medicine. The exploration of gene therapy not only underscores its transformative potential for rare genetic diseases but also illuminates the complexities and challenges that must be navigated to realize its full benefits for patients in need. Through this analysis, we aim to contribute to the ongoing discourse surrounding gene therapy and its implications for the future of medical treatment for rare genetic disorders.

2 Overview of Gene Therapy ​

2.1 Definition and Historical Context ​

Gene therapy represents a transformative approach in the treatment of rare genetic diseases, characterized by its ability to directly modify the genetic material within a patient's cells to address underlying pathogenic mutations. The field has evolved significantly, with advancements in both the understanding of genetic diseases and the development of therapeutic techniques.

Rare genetic diseases, often defined as conditions affecting fewer than 1 in 100,000 individuals, are primarily monogenic disorders caused by mutations in single genes. Historically, the concept of gene therapy emerged in the late 20th century, initially as a theoretical possibility. The first successful gene therapy trials in the early 2000s laid the groundwork for subsequent developments. Today, more than 4,000 protein-coding genes have been implicated in over 6,000 genetic diseases, underscoring the complexity and diversity of these conditions [2].

The primary modalities of gene therapy include gene supplementation, gene replacement, gene silencing, and gene editing. Gene supplementation and replacement involve delivering a functional copy of a gene to compensate for a defective one, while gene silencing techniques aim to inhibit the expression of harmful genes. Advanced methods such as CRISPR/Cas9 have introduced precise gene editing capabilities, allowing for the correction of mutations at specific loci within the genome [6].

In practice, gene therapy for rare diseases typically employs viral vectors, such as lentiviral or adeno-associated viruses (AAV), to facilitate the delivery of therapeutic genes into target cells. For instance, lentiviral vectors are commonly used in ex vivo gene therapy, where cells are extracted from the patient, genetically modified, and then reintroduced [7]. In vivo approaches involve direct delivery of the therapeutic vector into the patient’s body, often targeting specific tissues like the liver or central nervous system [2].

Recent advancements have seen the approval of several gene therapies for conditions such as spinal muscular atrophy (SMA) and certain metabolic disorders. For example, a single-dose gene therapy for SMA has demonstrated significant improvements in motor function that would not have been expected in the absence of treatment [7]. Similarly, gene therapy has shown promise in treating hematological disorders like β-thalassemia and sickle cell disease, where gene editing strategies are being developed to correct genetic defects in hematopoietic stem cells [8].

Despite these advancements, challenges remain in the field of gene therapy for rare diseases. Issues such as high development costs, complex manufacturing processes, and regulatory hurdles often impede access to these innovative treatments [9]. Furthermore, the need for personalized approaches in gene therapy necessitates a thorough understanding of individual genetic profiles, which can complicate the therapeutic landscape [3].

In summary, gene therapy for rare genetic diseases has transitioned from a theoretical concept to a clinical reality, offering new hope for patients with previously untreatable conditions. Through innovative delivery methods and ongoing research into gene editing technologies, the potential for effective and personalized treatment strategies continues to expand, paving the way for future advancements in the field.

2.2 Mechanisms of Gene Therapy ​

Gene therapy represents a transformative approach to treating rare genetic diseases by directly addressing the underlying genetic abnormalities that cause these conditions. Traditional treatments often provide limited relief and do not target the root causes of genetic disorders. In contrast, gene therapy aims to correct or compensate for defective genes, thereby offering the potential for precision treatment and even cures for various genetic diseases.

The mechanisms of gene therapy can be broadly categorized into several strategies, including gene replacement, gene supplementation, gene suppression, and gene editing. Each of these approaches has distinct advantages and limitations, which are crucial to consider in the context of clinical applications.

  1. Gene Replacement Therapy: This approach involves delivering a functional copy of a gene to replace a defective or missing gene. The use of viral vectors, such as adeno-associated viruses (AAV), is common in this strategy, as they can efficiently deliver the therapeutic gene into the target cells. For instance, in the case of spinal muscular atrophy (SMA), a single-dose gene therapy has shown significant progress in motor development when administered before the onset of symptoms (Kirschner & Cathomen, 2020).

  2. Gene Supplementation: This strategy is particularly useful for conditions where the body lacks a sufficient amount of a specific protein. Gene supplementation involves introducing additional copies of a gene to enhance protein production. Approaches such as lentiviral vector-modified autologous hematopoietic stem cell transplantation have been explored for rare genetic diseases, allowing for the systemic delivery of therapeutic genes (Hwu, 2024).

  3. Gene Suppression: This method targets overactive genes or pathways that contribute to disease pathology. By using techniques like antisense oligonucleotides or small interfering RNA (siRNA), gene suppression can effectively reduce the expression of harmful genes, thereby alleviating disease symptoms (Van Linthout et al., 2025).

  4. Gene Editing: CRISPR/Cas9 technology has emerged as a powerful tool for gene editing, allowing for precise modifications to the genome. This technique can correct mutations at specific loci, potentially restoring normal gene function. It has shown promise in treating conditions like sickle cell disease and β-thalassemia, where targeted edits can lead to significant clinical improvements (Quintana-Bustamante et al., 2022).

The application of these mechanisms in gene therapy is not without challenges. Issues such as vector packaging limitations, immunotoxicity, and the specificity of therapy remain significant hurdles. Furthermore, achieving long-term effectiveness and safety is crucial for the successful implementation of gene therapies in clinical settings (Qie et al., 2025).

In conclusion, gene therapy offers a multifaceted approach to treating rare genetic diseases by directly targeting the genetic underpinnings of these disorders. The continued development and refinement of gene therapy techniques hold great promise for enhancing treatment outcomes and improving the quality of life for patients affected by genetic diseases.

3 Applications in Rare Genetic Diseases ​

3.1 Successful Case Studies ​

Gene therapy represents a revolutionary approach in the treatment of rare genetic diseases, which are often caused by specific genetic abnormalities. This therapeutic strategy aims to address the underlying genetic defects, offering the potential for precise and, in some cases, curative treatments. Several successful case studies illustrate the efficacy of gene therapy in managing these conditions.

One prominent application of gene therapy is gene replacement, particularly exemplified in the treatment of spinal muscular atrophy (SMA). In SMA, a single-dose in vivo gene therapy has demonstrated remarkable success, leading to significant improvements in motor development that surpass expectations based on the natural disease progression. The therapy works by delivering a functioning copy of the SMN1 gene, which is critical for motor neuron health, thereby halting disease progression and enhancing quality of life for patients (Kirschner & Cathomen, 2020).

Another successful application of gene therapy can be seen in the treatment of severe combined immunodeficiency (ADA-SCID). Here, gene therapy has effectively restored immune function by introducing a functional copy of the ADA gene into the patient's hematopoietic stem cells. This innovative approach has transformed the prognosis for patients who previously faced life-threatening infections due to their immunodeficiency (Qasim et al., 2007).

Moreover, gene therapy has also made strides in addressing rare metabolic disorders. For instance, advancements in the treatment of rare genetic conditions like CTNNB1 syndrome in Slovenia have shown promising results. The use of viral vectors for gene delivery has enabled researchers to successfully target specific genetic mutations, leading to significant clinical improvements (Grošelj et al., 2025).

The development of gene therapies has been bolstered by innovations in vector design and delivery systems. For example, the use of adeno-associated viral (AAV) vectors has become a standard in the field, allowing for effective gene delivery with a favorable safety profile. The versatility of AAV vectors facilitates both in vivo and ex vivo applications, making them suitable for a wide range of genetic disorders (Bueren & Auricchio, 2023).

Despite the remarkable successes, the field of gene therapy still faces challenges. Issues such as vector packaging limitations, immunotoxicity, and the need for precise delivery mechanisms remain significant hurdles that researchers are actively addressing. The focus on optimizing these parameters is essential for enhancing the long-term effectiveness and safety of gene therapies (Qie et al., 2025).

In conclusion, gene therapy has emerged as a powerful tool in the treatment of rare genetic diseases, with several successful case studies demonstrating its potential. The ability to directly target and correct genetic defects offers hope for patients with conditions previously deemed untreatable, marking a significant advancement in the field of medicine. Continued research and innovation will be crucial in overcoming existing challenges and expanding the applicability of gene therapies to a broader range of genetic disorders.

3.2 Ongoing Clinical Trials ​

Gene therapy represents a transformative approach in the treatment of rare genetic diseases, leveraging advancements in genetic engineering and vector technology to address the underlying genetic causes of these conditions. This innovative therapeutic strategy primarily focuses on gene replacement therapy, which can be delivered through in vivo or ex vivo methods, predominantly utilizing viral vectors to introduce therapeutic genes into target cells.

In Slovenia, significant progress has been made in the field of gene therapy since 2018, with successful trials addressing various rare diseases. Notable achievements include treatments for spinal muscular atrophy and rare metabolic disorders, along with pioneering work on CTNNB1 syndrome. The implementation of immune gene therapy, particularly the use of IL-12 adjuvant therapy for cancer, further exemplifies the diverse applications of gene therapy in treating rare conditions [3].

The landscape of gene therapy for ultrarare diseases is also evolving, as only one of the twelve approved gene therapies specifically targets conditions with fewer than 1:100,000 cases. Various approaches, such as lentiviral vector-modified autologous CD34+ hematopoietic stem cell transplantation and systemic delivery of adeno-associated virus (AAV) vectors, have been explored for their efficacy in treating these rare genetic disorders [2].

Clinical trials play a crucial role in the advancement of gene therapy. The FDA has approved multiple gene therapies, including Kynamro for familial hypercholesterolemia, Exondys51 for Duchenne muscular dystrophy, and Spinraza for spinal muscular atrophy. These approvals reflect the ongoing commitment to address the needs of patients suffering from severe inherited conditions [10].

Despite the promising results and increasing number of clinical applications, challenges remain in the gene therapy field. Issues such as cost, distribution, efficacy, and long-term safety are significant hurdles that must be addressed to ensure equitable access to these innovative therapies for patients with rare diseases [3][5]. The establishment of comprehensive clinical infrastructures, such as the Centre for Rare Diseases and the Centre for the Technologies of Gene and Cell Therapy in Slovenia, demonstrates a proactive approach to overcoming these challenges and enhancing patient care [3].

Overall, gene therapy is rapidly becoming a cornerstone in the treatment of rare genetic diseases, with ongoing clinical trials and research aimed at refining techniques and expanding the range of treatable conditions. As the field progresses, collaborative efforts among researchers, healthcare providers, and regulatory bodies will be essential to realize the full potential of gene therapy in transforming the lives of patients with rare genetic disorders.

4 Challenges and Limitations ​

4.1 Safety Concerns ​

Gene therapy represents a promising approach for treating rare genetic diseases by directly addressing the underlying genetic abnormalities responsible for these conditions. This innovative strategy aims to provide precision treatment, potentially leading to cures rather than mere management of symptoms. Various gene therapy techniques have been developed, including gene replacement, gene suppression, gene supplementation, and gene editing, each with distinct advantages and limitations [1].

Despite the advancements in gene therapy, several challenges and limitations persist. One of the primary concerns is the safety of these therapies. The use of viral vectors for gene delivery, while effective, can raise immunogenicity issues, leading to adverse immune responses. Furthermore, the specificity of therapy is crucial; unintended effects can arise if the therapeutic gene integrates into the wrong location in the genome, potentially disrupting other essential genes [3].

Moreover, the complexity of the human immune response poses additional challenges. Immunotoxicity can occur, resulting in inflammation or other immune-related complications. These safety concerns necessitate rigorous preclinical and clinical evaluations to assess the long-term effects of gene therapies [11].

Another significant limitation is the vector packaging capacity. Current vectors may not be able to accommodate larger genes or multiple genes required for some genetic diseases, which can hinder the efficacy of the treatment [1]. Additionally, the subcellular localization of therapeutic cargos can affect the efficiency of gene delivery, further complicating the treatment process [1].

The regulatory landscape for gene therapies also presents challenges. Many gene therapies are developed for ultra-rare diseases, which often do not attract sufficient commercial interest due to the small patient populations involved. This lack of financial incentive can impede the development and availability of effective treatments [4].

Cost remains a significant barrier as well; the high price of gene therapies can limit access for patients, particularly in healthcare systems that are not structured to accommodate such expensive interventions [12].

In summary, while gene therapy holds great potential for treating rare genetic diseases, significant challenges remain, particularly concerning safety, vector limitations, regulatory hurdles, and cost. Ongoing research and innovative solutions are essential to address these issues and improve the accessibility and efficacy of gene therapies for patients with rare genetic disorders [10].

4.2 Ethical Considerations ​

Gene therapy presents a transformative approach to treating rare genetic diseases by directly addressing the underlying genetic abnormalities. This therapeutic strategy aims to rectify the root causes of these conditions, thereby offering the potential for precision treatment and even cures. Various methodologies within gene therapy, such as gene replacement, gene suppression, gene supplementation, and gene editing, are utilized to target different genetic disorders affecting various body systems. For instance, gene replacement therapy involves delivering a functional copy of a gene to compensate for a defective one, while gene editing techniques like CRISPR/Cas9 enable precise alterations to the genome to correct mutations (Qie et al. 2025; Hwu 2024).

Despite the promising advancements in gene therapy, several challenges and limitations hinder its widespread application. These include technical hurdles such as vector packaging limitations, which affect the efficiency of gene delivery systems; immunotoxicity, which can provoke adverse immune responses; and concerns regarding therapy specificity and the subcellular localization of therapeutic cargos. The immunogenicity of these therapies also poses a significant barrier, as the body may mount an immune response against the delivered genetic material or the vectors used for delivery (Qie et al. 2025; Iyer et al. 2021).

Ethical considerations are paramount as gene therapies progress, particularly in pediatric populations where many of the targeted diseases are ultrarare and life-limiting. Ethical challenges include evaluating the risks and potential benefits of these therapies, ensuring fair participant selection in clinical trials, and engaging effectively with patient communities. The complexity of informed consent, especially for minors, further complicates the ethical landscape. Moreover, the commercialization of gene therapies raises questions about equitable access, as traditional regulatory and reimbursement frameworks may not adequately address the needs of small patient populations (Iyer et al. 2021; Grošelj et al. 2025).

In summary, while gene therapy holds significant promise for treating rare genetic diseases, it is accompanied by substantial challenges and ethical dilemmas that must be navigated carefully to ensure safe, effective, and equitable therapeutic options for patients. Achieving delivery specificity, long-term effectiveness, and safety remains crucial for the future development of gene therapies targeting genetic diseases (Qie et al. 2025; Booth & Aiuti 2023).

4.3 Regulatory Hurdles ​

Gene therapy has emerged as a transformative approach for treating rare genetic diseases by directly addressing the underlying genetic defects. The advancements in gene therapy techniques, including gene replacement, gene suppression, gene supplementation, and gene editing, offer precision treatment options that were previously unattainable with traditional therapies. These methods aim to correct or replace defective genes responsible for various genetic disorders, thereby providing potential cures or significant symptom relief for affected individuals[1].

However, the application of gene therapy for rare diseases is not without its challenges and limitations. One of the most significant hurdles is the regulatory environment, which often lags behind the rapid advancements in gene therapy technologies. The regulatory frameworks established for traditional therapies are often ill-suited for the unique characteristics of gene therapies, particularly those targeting rare and ultrarare diseases. With over 10,000 identified rare diseases, and only about 5% having FDA-approved treatments, there is a substantial unmet need for innovative regulatory solutions that can facilitate the development and approval of gene therapies[13].

Key regulatory challenges include the mismatch between existing paradigms and the nature of gene therapies, which often require novel clinical trial designs and flexible manufacturing processes. The complexities involved in navigating the regulatory pathways for treatments affecting small patient populations can be prohibitive. These challenges are exacerbated by the need for extensive data on safety and efficacy, which may be difficult to obtain given the limited patient populations[4].

Moreover, there are significant logistical issues related to commercialization and reimbursement of gene therapies. The high costs associated with developing advanced therapy medicinal products (ATMPs) and the complexities of their manufacturing processes restrict access to these potentially life-saving treatments. Innovative payment models and a better alignment of payer coverage policies with FDA-approved indications are critical to overcoming these barriers and ensuring that patients have access to the therapies they need[12].

Additionally, ethical considerations surrounding gene therapy, particularly with techniques such as CRISPR-Cas9, present further challenges. Issues such as off-target effects, germline editing, and equitable access to therapies require ongoing ethical oversight and public discourse to ensure that the benefits of gene therapy can be realized without compromising safety or ethical standards[14].

In summary, while gene therapy holds immense promise for treating rare genetic diseases, the path to successful implementation is fraught with challenges, particularly in the regulatory landscape. Addressing these regulatory hurdles through innovative reforms, flexible trial designs, and comprehensive reimbursement strategies will be essential for advancing gene therapies and improving patient access to these groundbreaking treatments[2][5].

5 Future Directions ​

5.1 Innovations in Delivery Methods ​

Gene therapy has emerged as a revolutionary approach to treating rare genetic diseases by delivering therapeutic genes to target cells, correcting pathogenic mutations, and modulating genes responsible for disease progression. This therapeutic modality is particularly significant for rare diseases, which often have limited treatment options due to their low incidence and the associated challenges in commercialization and research investment [12].

The delivery of therapeutic genes is critical to the success of gene therapy. Recent advancements have focused on enhancing the efficiency and safety of gene delivery methods. For instance, the use of viral vectors, such as adeno-associated viruses (AAVs), has been widely explored. These vectors can deliver genes directly into the target cells, either through in vivo or ex vivo methods. AAV vectors have been notably effective in treating conditions like spinal muscular atrophy (SMA), with the FDA approving multiple gene therapies that utilize these vectors [9].

Innovations in delivery methods also encompass non-viral approaches. Nanotechnology has been integrated into gene therapy to develop novel carriers, such as carbon quantum dots (CQDs), which possess unique physicochemical properties, including small size and minimal toxicity. These carriers can enhance the precision and effectiveness of gene delivery, thus holding promise for personalized medicine [15]. Additionally, mRNA therapies are gaining traction, building on the success of mRNA COVID-19 vaccines. These therapies aim to deliver mRNA encoding functional proteins directly to cells, providing an alternative to traditional gene therapy approaches [11].

The exploration of new delivery systems is vital as challenges remain in ensuring long-term safety and efficacy. Researchers are actively investigating new vectors and optimizing delivery routes to improve therapeutic outcomes [9]. For example, local gene delivery methods, such as intratumoral infusion, can enhance transfection efficiency while minimizing systemic toxicity [16]. Furthermore, the integration of gene editing technologies, such as CRISPR/Cas9, offers additional avenues for correcting genetic defects at their source, which could significantly alter the landscape of treatment for rare genetic disorders [11].

Overall, the future of gene therapy for rare genetic diseases lies in the continuous innovation of delivery methods, which will enhance the precision, safety, and efficacy of treatments. As these technologies evolve, they are expected to broaden the therapeutic options available for patients suffering from rare genetic conditions, ultimately improving their quality of life and health outcomes [17].

5.2 Potential for Personalized Medicine ​

Gene therapy represents a transformative approach in the treatment of rare genetic diseases, focusing on addressing the underlying genetic mutations that cause these conditions. The application of gene therapy has gained momentum due to significant advancements in genetic technologies, allowing for more precise and effective interventions.

Gene therapy operates primarily through the delivery of genetic material to target cells using various vectors, aiming to correct pathogenic mutations or modulate gene expression responsible for disease progression. For instance, the recent approval of gene therapies by the FDA highlights the potential of this approach, with specific therapies targeting hematologic and rare diseases. Notably, in 2023, the FDA approved three clinical applications for spinal muscular atrophy (SMA) utilizing viral vectors administered via intravenous and intrathecal routes, showcasing the effectiveness of gene therapy in treating neurodegenerative conditions (Wang et al., 2025) [9].

The personalized medicine aspect of gene therapy is particularly compelling. By tailoring treatment based on an individual's genetic profile, gene therapy offers the potential for precision medicine. This is exemplified in the case of genetic muscular disorders, where strategies such as gene replacement, suppression, and editing are employed to provide targeted therapeutic interventions. Each patient's unique genetic makeup informs the choice of therapy, thus enhancing the likelihood of treatment success (Qie et al., 2025) [1].

Moreover, the development of next-generation sequencing (NGS) technologies has facilitated the accurate molecular diagnosis of rare genetic disorders, enabling the identification of disease-causing mutations. This precision in diagnosis is crucial for the successful implementation of gene therapies, as it allows for the selection of appropriate therapeutic targets (Zaneveld et al., 2013) [18].

Despite the promise of gene therapy, challenges remain. Issues such as vector packaging limitations, immunotoxicity, and the specificity of therapeutic delivery need to be addressed to optimize the efficacy and safety of gene therapies (Qie et al., 2025) [1]. Furthermore, the commercialization of gene therapies for ultrarare diseases is complicated by regulatory pathways that may not accommodate small patient populations, necessitating innovative solutions to enhance accessibility (Booth & Aiuti, 2023) [5].

In summary, gene therapy holds substantial potential for treating rare genetic diseases, particularly through the lens of personalized medicine. As research progresses, ongoing efforts to refine gene delivery methods, improve diagnostic capabilities, and address regulatory challenges will be critical in realizing the full potential of gene therapy for affected individuals.

6 Conclusion ​

Gene therapy has emerged as a revolutionary approach to treating rare genetic diseases, providing new hope for patients who previously had limited treatment options. The primary findings of this report underscore the effectiveness of gene therapy in directly addressing the genetic mutations responsible for these conditions, as evidenced by successful case studies such as spinal muscular atrophy and severe combined immunodeficiency. The advancements in gene therapy techniques, including gene replacement, supplementation, suppression, and editing, have paved the way for innovative treatment strategies that not only alleviate symptoms but also offer potential cures. However, the field is still grappling with significant challenges, including safety concerns, high costs, regulatory hurdles, and ethical considerations. As the landscape of gene therapy continues to evolve, future research must focus on enhancing delivery methods, optimizing vector technologies, and developing personalized treatment approaches that take into account individual genetic profiles. Collaborative efforts among researchers, healthcare providers, and regulatory bodies will be essential in overcoming these barriers and ensuring equitable access to these transformative therapies for patients with rare genetic disorders. Ultimately, the promise of gene therapy lies in its potential to redefine the standard of care for rare genetic diseases, improving the quality of life for countless individuals worldwide.

References ​

  • [1] Beibei Qie;Jianghua Tuo;Feilong Chen;Haili Ding;Lei Lyu. Gene therapy for genetic diseases: challenges and future directions.. MedComm(IF=10.7). 2025. PMID:39949979. DOI: 10.1002/mco2.70091.
  • [2] Wuh-Liang Hwu. Gene therapy for ultrarare diseases: a geneticist's perspective.. Journal of biomedical science(IF=12.1). 2024. PMID:39138523. DOI: 10.1186/s12929-024-01070-1.
  • [3] Urh Grošelj;Marko Kavčič;Ana Drole Torkar;Jan Kafol;Duško Lainšček;Roman Jerala;Matjaž Sever;Samo Zver;Gregor Serša;Maja Čemažar;Primož Strojan;Aleš Grošelj;Mojca Žerjav Tanšek;Špela Miroševič;Simona Ivančan;Tomaž Prelog;David Gosar;Jasna Oražem Mrak;Matej Mlinarič;Sara Bertok;Jernej Kovač;Jana Kodrič;Saba Battelino;Marko Pokorn;Alojz Ihan;Janez Jazbec;Tadej Battelino;Damjan Osredkar. Gene therapy of rare diseases as a milestone in medicine - overview of the field and report on initial experiences in Slovenia.. Orphanet journal of rare diseases(IF=3.5). 2025. PMID:40474241. DOI: 10.1186/s13023-025-03828-8.
  • [4] Thomas A Fox;Claire Booth. Improving access to gene therapy for rare diseases.. Disease models & mechanisms(IF=3.3). 2024. PMID:38639083. DOI: 10.1242/dmm.050623.
  • [5] Claire Booth;Alessandro Aiuti. Realizing the Potential of Gene Therapies for Rare and Ultra-Rare Inherited Diseases.. Human gene therapy(IF=4.0). 2023. PMID:37624746. DOI: 10.1089/hum.2023.127.
  • [6] Tingting Wu;Yu Hu;Liang V Tang. Gene therapy for polygenic or complex diseases.. Biomarker research(IF=11.5). 2024. PMID:39232780. DOI: 10.1186/s40364-024-00618-5.
  • [7] Janbernd Kirschner;Toni Cathomen. Gene Therapy for Monogenic Inherited Disorders.. Deutsches Arzteblatt international(IF=7.1). 2020. PMID:33637169. DOI: .
  • [8] Oscar Quintana-Bustamante;Sara Fañanas-Baquero;Mercedes Dessy-Rodriguez;Isabel Ojeda-Pérez;Jose-Carlos Segovia. Gene Editing for Inherited Red Blood Cell Diseases.. Frontiers in physiology(IF=3.4). 2022. PMID:35418876. DOI: 10.3389/fphys.2022.848261.
  • [9] Lingling Wang;Lin Ma;Zihan Gao;Ying Wang;Jiaoxue Qiu. Significance of gene therapy in neurodegenerative diseases.. Frontiers in neuroscience(IF=3.2). 2025. PMID:40406043. DOI: 10.3389/fnins.2025.1515255.
  • [10] Rahul G Ingle;Gehan M Elossaily;Mohd Nazam Ansari;Shivani Makhijani. Unlocking the potential: advancements and applications of gene therapy in severe disorders.. Annals of medicine(IF=4.3). 2025. PMID:40526097. DOI: 10.1080/07853890.2025.2516697.
  • [11] Paul J L Schürmann;Stijn P E van Breda Vriesman;Jose A Castro-Alpízar;Sander A A Kooijmans;Edward E S Nieuwenhuis;Raymond M Schiffelers;Sabine A Fuchs. Therapeutic Application of mRNA for Genetic Diseases.. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology(IF=8.2). 2025. PMID:40415711. DOI: 10.1002/wnan.70019.
  • [12] Diane Berry;Carolyn Hickey;Lisa Kahlman;James Long;Christina Markus;Caitlin K McCombs. Ensuring patient access to gene therapies for rare diseases: Navigating reimbursement and coverage challenges.. Molecular therapy. Methods & clinical development(IF=4.7). 2025. PMID:39897638. DOI: 10.1016/j.omtm.2024.101403.
  • [13] Diane Berry;Kate Donigan;Lisa Kahlman;James Long;Christina Markus;Caitlin K McCombs. Optimizing regulatory frameworks for gene therapies in rare diseases: Challenges and solutions.. Molecular therapy. Methods & clinical development(IF=4.7). 2024. PMID:39720694. DOI: 10.1016/j.omtm.2024.101386.
  • [14] Emile Youssef;Brandon Fletcher;Dannelle Palmer. Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology.. Frontiers in medicine(IF=3.0). 2024. PMID:39871848. DOI: 10.3389/fmed.2024.1527600.
  • [15] Hazha Omar Othman;Esra Tariq Anwer;Diyar Salahuddin Ali;Rebwar Omar Hassan;Elnaz Ehsan Mahmood;Rayan Abubakir Ahmed;Rozhan Fathulla Muhammad;Slim Smaoui. Recent advances in carbon quantum dots for gene delivery: A comprehensive review.. Journal of cellular physiology(IF=4.0). 2024. PMID:38454776. DOI: 10.1002/jcp.31236.
  • [16] Lili Zhao;Jinhui Wu;He Zhou;Ahu Yuan;Xiang Zhang;Feng Xu;Yiqiao Hu. Local gene delivery for cancer therapy.. Current gene therapy(IF=3.3). 2011. PMID:21711227. DOI: 10.2174/156652311797415854.
  • [17] Juan A Bueren;Alberto Auricchio. Advances and Challenges in the Development of Gene Therapy Medicinal Products for Rare Diseases.. Human gene therapy(IF=4.0). 2023. PMID:37694572. DOI: 10.1089/hum.2023.152.
  • [18] Jacques Zaneveld;Feng Wang;Xia Wang;Rui Chen. Dawn of ocular gene therapy: implications for molecular diagnosis in retinal disease.. Science China. Life sciences(IF=9.5). 2013. PMID:23393028. DOI: 10.1007/s11427-013-4443-y.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Gene Therapy · Rare Genetic Diseases · Molecular Biology · Genetic Engineering · Personalized Medicine

© 2025 MaltSci